Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

million and escalating royalties on sales commensurate with the current stage of development of the product if dirucotide (MBP8298) is commercialized. The completion of the licensing agreement with Lilly resulted in a one time payment of a $9.0 million licensing bonus to Corporation personnel, paid in February, 2008.

Financial Results

The consolidated net loss for the first quarter ended March 31, 2008 was $6.7 million or ($0.07) per share compared to a consolidated net loss of $12.9 million or ($0.17) per share for the first quarter of the previous year.

Revenue for the three months ended March 31, 2008 was $12.8 million compared to $nil for the first three months of the previous year. The revenue is the result of recognizing a portion of the upfront payment received on the completion of the licensing agreement with Eli Lilly and Company.

Total consolidated expenses for the three months ended March 31, 2008 were $22.2 million compared to $13.3 million for the first three months of the previous year.

Research and development expenses for the first quarter ended March 31, 2008 totaled $13.1 million compared to $10.3 million for the first quarter of the previous year. The increase of $2.8 million is primarily attributable to: a one time licensing bonus payment of $3.4 million to research and development personnel, a decrease in drug manufacturing costs of $1.4 million and a decrease in clinical trial expenses of $1.7 million. It is expected that total research and development expenses will remain constant over the next two years as the MAESTRO-01 and MINDSET-01 clinical trials near completion while the MAESTRO-02 and MAESTRO-03 trials increase in number of patients under treatment.

General and administrative expenses were $8.7 million for the three months ended March 31, 2008 compared to $2.6 million for the three months ended March 31, 2007. The increase is primarily attributable to: a one time licensing bonus payment of $5.6
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Deep Research Report ... professional and in-depth research report on the ... Seaweed Fertilizer information, including Seaweed Fertilizer definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
(Date:8/21/2014)... N.Y. (PRWEB) August 21, 2014 The ... the first private college in the Mid-Hudson Region to ... will now begin accepting applications from qualified “high-technology” businesses ... “We are very pleased to have been selected for ... Governor Cuomo’s transformative initiative to stimulate economic development in ...
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... biopharmaceutical contract development and manufacturing organization (CMO) announced ... Pharmaceuticals, Inc., an oncology company focused on the ... cancer, to manufacture the anti-prostate specific membrane antigen ... product candidate. Under the agreement the antibody ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Wis. -- Gov. Jim Doyle says taxpayers will ... total of nearly $80 million over the lifetime of ... and services, including a number of technology areas. , ... Accountability, Consolidation, and Efficiency (ACE) Initiative to ensure ...
... of Milwaukee is one of six first-year college students from ... Online's "Project Freshman," a new documentary series that will be ... Friday, Sept. 23. New episodes will air every Thursday. The ... were given digital video cameras and were trained in their ...
... -- The Wisconsin Technology Council has teamed with PropertyDrive, ... database of commercial real estate on the Tech Council ... on the site's Resource Center, Commercial Property Search. , ... locate or expand in Wisconsin the ability to search ...
Cached Biology Technology:
(Date:8/21/2014)... by an international standards process, will be available soon ... invited review published in the OnlineFirst version of ... official journal of the American Society for Parenteral and ... the occurrence of misconnection that can be harmful and ... used to join medical devices, components, and accessories to ...
(Date:8/21/2014)... has successfully replicated one of the crucial steps in ... sunlight which could manufacture hydrogen as a fuel. , ... an exciting prospect to use them to create hydrogen, ... Hingorani, from the ARC Centre of Excellence for Translational ... Hydrogen offers potential as a zero-carbon replacement for petroleum ...
(Date:8/21/2014)... pancreas digesting itself resulting in severe abdominal pain, vomiting ... 20,000 patients are diagnosed with the disease resulting in ... is restricted to intravenous fluid and nutritional support. ... Sciences, who led the research, said "The major causes ... and excessive alcohol intake combined with a high fat ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2
... is available in Polish . A ... mouse embryos can repair damaged brain circuitry and partially normalize ... obese due to a genetic deficiency. This proof-of-principle discovery represents ... which researchers hope might one day be used to repair ...
... National Taiwan University researchers have successfully manipulated the life span ... remove and restore protein functions related to yeast aging. ... in yeast acts like a life span clock: It is ... age. In a report in the September 16 edition ...
... and the University of Geneva have discovered a genetic mechanism ... genes play only a secondary role. The research published in ... mechanism is found in a DNA sequence that was thought, ... enhancers which, when combined with one another, modulate the activity ...
Cached Biology News:Metabolic defects in mice corrected with transplanted embryonic neurons 2Hopkins scientists turn on fountain of youth in yeast 2Finger (mal)formation reveals surprise function of desert DNA 2
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: